MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation) (CSE: MPX) (OTC: MPXEF) - Investor Dashboard

MPX Bioceutical Corp
CSE Symbol: MPX
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 83
Established: 1974
CEO: Scott Boyes


Fiscal Year-End:  March
Exchanges: OTC, CSE
Sector: Financial
Auditor  Deloitte
Headquarters: Toronto, ON
States w/Operations:  AZ

Financials (09/30/17)

Cash on hand: C$4.8mm
Fixed Investment: C$10.2mm
Shareholders’ Equity: C$39.2mm
Revenues – Last Quarter: C$4.4mm
Adj. Gross Margin : 42.6%
EPS : -C$0.02

Capital Structure (12/22/18)

Last Financing: 56.3mm units at C$0.47
Basic Shares: 331.2mm
Warrants: 66.1mm
Options: 25.3mm
Diluted Shares: 422.6mm

Company Brief

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation) is a vertically integrated, multi-state cannabis operation which provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona (3rd under development). While MPX does not directly own, possess or sell cannabis or cannabis-infused products, it does provide substantial support and exerts influence through its management agreements.

In Arizona, the company has developed a large seed bank with high-demand strains, a reputation for exceptional customer service and strong brand awareness. It has also developed award-winning concentrates under the Melting Point Extracts (MPX) brand. It will be leveraging this experience and its brands in Massachusetts, where it has completed the acquisition of a 51% interest in IMT, LLC and Fall River Developments, LLC (“FRD”), Massachusetts registered companies active in the cannabis space.

Through its proven access to capital on the public markets, as well as the cash flow positive nature of its current operations, MPX is extremely well positioned to pursue an aggressive but controlled acquisition strategy. The Company intends to follow a multi-state strategy and has already lined up a number of attractive opportunities in Maryland and Nevada. MPX intends to leverage its brand strength and take advantage of its technical and operational expertise as it enters into new markets.

Featured Video

New West Summit


  • Leadership position in strong and growing Arizona medical market with highly profitable operations
  • Multi-state strategy, with operations in Massachusetts and pending acquisitions in Maryland and Nevada
  • US$38mm equity capital raised in early 2017
  • Strategic equity investor in Hi-Med, LLC, which has also provided a US$25mm revolving credit facility
  • ACMPR applicant

Growth Strategy

  • Organic growth with existing Arizona operations, including additional dispensary openings under the Health for Life brand and expansion of MPX concentrates brand
  • Additional acquisitions in AZ, including pending transaction
  • Expansion into additional states, with pending acquisitions in MD and NV
  • New development in high-potential, early-stage markets with strong barriers to entry


  • Access to capital
  • Management with proven operational expertise
  • Strong brands in Arizona (MPX and H4L)
  • Highly profitable business model with focus on branded extracts
  • Exclusive rights to Roto-Gro system in AZ and NV

Snapshot of MPX Bioceutical Corporation Assets
View facilities and pending acquisition targets

Brands & Products

Cultivation & Production


Institutional Analyst Coverage

Echelon Wealth Partners

Curated Stories & News

Visit MPX Bioceutical Corporation,

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. MPX Bioceutical Corporation is a client of NCV Media, LLC. Read our full disclaimer.